omniture
药明生物 WuXi Biologics

Latest News

Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day

SHANGHAI, June 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company wit...

2020-06-19 17:56 430

WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing

* One of few third-party biosafety testing providers certified by EMA GMP standards inChina even ...

2020-06-16 08:00 395

WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States

CRANBURY, NJ and SHANGHAI, June 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a gl...

2020-06-09 08:00 245

WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories

SHANGHAI and NEW YORK, May 28, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global...

2020-05-28 08:00 586

WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States

SHANGHAI and WORCESTER, Mass., May 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), ...

2020-05-19 08:00 796

WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

SHANGHAI and HOUSTON, April 30, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a glob...

2020-04-30 19:00 201

WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility

* First GMP facility in WuXi Biologics to use robotic aseptic filling line for biologics * Demo...

2020-04-28 08:00 529

WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany

SHANGHAI and LEVERKUSEN, Germany, April 22, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269....

2020-04-22 08:00 487

WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection

SUZHOU, China, April 13, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global compa...

2020-04-14 08:00 5573

WuXi Biologics Achieved Remarkable Results in 2019

57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjuste...

2020-03-26 21:32 4710

WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland

DUNDALK, Ireland, March 11, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading g...

2020-03-11 08:00 483

WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a ...

2020-02-25 21:30 633

WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ope...

2020-02-24 08:00 4295

WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global op...

2020-02-18 18:42 421

WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Vaccines, a new vaccine Contract Development and Manuf...

2020-02-18 18:18 614

WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak

SHANGHAI, Feb. 11, 2020 /PRNewswire/ -- WuXi Biologics is closely monitoring the coronavirus outbre...

2020-02-12 08:00 5735

WuXi Biologics Provides Operation Update Related to the Coronavirus Outbreak

SHANGHAI, Jan. 29, 2020 /PRNewswire/ -- The coronavirus outbreak is having a potentially significan...

2020-01-29 10:44 671

WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus

SHANGHAI, Jan. 29, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ope...

2020-01-29 10:00 1172

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

* First drug product facility in Europe to complement WuXi Biologics' existing commercial manufac...

2020-01-16 10:39 16669

WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

* The 12th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing ...

2020-01-09 17:10 1381
12345